Within the context of a medical cardiology practice, especially navigating among patients with inadequate responses to ezetimibe and/or statin intolerance or resistance, how do you sequence PCSK9 inhibitors in your LDL-C lowering treatment plans?

Name: Within the context of a medical cardiology practice, especially navigating among patients with inadequate responses to ezetimibe and/or statin intolerance or resistance, how do you sequence PCSK9 inhibitors in your LDL-C lowering treatment plans?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Robert Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY